Global Urological Cancer Market to 2022 - Strong Growth Driven by Rising Prevalence, Increased Uptake of Hormone Therapies and Approval of Novel Biologics

GBI Research
143 Pages - GBI10558
$4,995.00

Summary

Urological cancers are thought to account for 19.5% of global cancer prevalence, with kidney, prostate, testicular and bladder cancer – the key indications covered in this report – accounting for the majority of that figure. Urological cancers affect the male and female urinary tract and the male reproductive organs. Prostate cancer is the most prevalent of these malignancies.

A number of common etiologic factors have been strongly characterized as raising the risk of developing urological cancers, including age, chronic inflammation, gender, obesity, tobacco usage and heritable cancer syndromes. The risk of cancer increases greatly in patients over the age of 65. Populations in developed countries are projected to become increasingly aged and show rising obesity incidence, which will drive both cancer prevalence and revenue growth for its treatments.

Hormone therapies for prostate cancers and angiogenesis inhibitors for renal cell carcinoma are currently the most commercially successful urological cancer drugs. However, there has been a shift towards the clinical testing of cancer immunotherapies – such as Opdivo, which was recently approved for renal cell carcinoma. The forecast period will also witness the approval of a greater number of targeted therapies, which by their nature have less toxicity associated with their use, and as a result can be administered to patients with poor performance statuses, therefore increasing the overall survival of this group and the number of treatment cycles they may receive.

Scope

- Global revenues for the urological cancer market are forecast to grow at a Compound Annual Growth Rate (CAGR) of 10.39%, from $17.9 billion in 2015 to $35.9 billion in 2022. Which drugs will achieve blockbuster status and how will the key player companies perform during the forecast period?
- The urologic oncology pipeline is large and diverse, and contains 817 products. How does the composition of the pipeline compare with that of the existing market?
- What mechanisms of action and molecule types are most common for pipeline drugs being trialed in the various key indications?
- How will the market shares and CAGRs of the top 20 companies compare within this therapy area?
- What proportion of the key players’ revenues will be attributable to urological cancers?

Reasons to buy

This report will allow you to -
- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis
- Visualize the composition of the urological cancer market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players
- Analyze the urological cancer pipeline and stratify by stage of development, molecule type and molecular target, with a granular breakdown across key indications
- Understand the growth in patient epidemiology and market revenues for the urological cancer market globally and across the key players and product types  
- Stratify the market in terms of the split between generic and premium products, and assess the role of these product types in the treatment of the various urological cancers
- Identify commercial opportunities in the urological cancer deals landscape by analyzing trends in licensing and co-development deals

'

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 6
2 Introduction 9
2.1 Disease Cluster Introduction 9
2.2 Symptoms 9
2.3 Etiology and Pathophysiology 10
2.3.1 Etiology 10
2.3.2 Pathophysiology 11
2.4 Co-morbidities and Complications 13
2.5 Epidemiology Patterns; Prevalence, Patient Segmentation, and Diagnostic and Treatment Usage Rates 13
2.5.1 Bladder Cancer 14
2.5.2 Kidney Cancer 15
2.5.3 Prostate Cancer 15
2.5.4 Testicular Cancer 16
2.6 Treatment 17
2.6.1 Chemotherapy 17
2.6.2 Surgery and Radiation Therapy 19
2.6.3 Hormonal Therapies 21
2.6.4 Targeted Therapies 22
3 Key Marketed Products 23
3.1 Overview 23
3.2 Zytiga (abiraterone acetate) 23
3.3 Xtandi (enzalutamide) 25
3.4 Sutent (sunitinib malate) 26
3.5 Votrient (pazopanib hydrochloride) 27
3.6 Inlyta (axitinib) 28
3.7 Jevtana (cabazitaxel) 29
3.8 Xofigo (radium Ra 223 dichloride) 31
3.9 Provenge (sipuleucel-T) 32
3.10 Opdivo (nivolumab) – Bristol-Myers Squibb 33
3.11 Conclusion 34
4 Pipeline Landscape Assessment 35
4.1 Overview 35
4.2 Pipeline Development Landscape 36
4.3 Molecular Targets in the Pipeline 39
4.4 Clinical Trials 43
4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target 44
4.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target 48
4.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target 52
4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target 56
4.5 Conclusion 60
4.6 Assessment of Key Pipeline Products 61
4.6.1 Atezolizumab – Roche 61
4.6.2 Durvalumab – AstraZeneca 62
4.6.3 Durvalumab + Tremelimumab – MedImmune 63
4.6.4 Apalutamide – Johnson & Johnson 64
4.6.5 Avelumab – Merck KGaA 65
4.6.6 Tivozanib – EUSA Pharma 66
4.6.7 Eoquin – Spectrum Pharmaceuticals 67
4.6.8 Prostvac – Bavarian Nordic 68
4.7 Conclusion 69
5 Multi-Scenario Market Forecast to 2022 70
5.1 Overall Market Size 70
5.2 Generic Penetration 72
5.3 Revenue Forecast by Molecular Target 75
5.3.1 Androgen Receptor Antagonists 75
5.3.2 Programmed Cell Death Protein 1 Inhibitor 76
5.3.3 VEGF Inhibitors 76
5.3.4 GnRH Inhibitors 77
5.3.5 Tubulin Inhibitors 78
5.3.6 CTLA-4 Inhibitors 79
6 Company Analysis and Positioning 80
6.1 Revenue and Market Share Analysis by Company 81
6.1.1 Pfizer – Will a Patent Cliff Be Avoided Following the Expiries of Sutent and Inlyta? 85
6.1.2 Novartis – How Will Upcoming Patent Expiries Affect Urological Cancer Revenues? 86
6.1.3 Johnson & Johnson – How Will Zytiga Perform in an Increasingly Competitive Prostate Cancer Treatment Market? 87
6.1.4 Astellas – What Will Become of Xtandi? 88
6.1.5 AstraZeneca – Will Sales Revenues Increase over the Forecast Period? 88
6.1.6 Bristol-Myers Squibb – How Will Cancer Immunotherapies Affect Urological Cancers? 89
6.2 Company Landscape 90
6.3 Marketed and Pipeline Portfolio Analysis 91
7 Strategic Consolidations 95
7.1 Licensing Deals 95
7.1.1 Deals by Region, Year and Value 95
7.1.2 Deals by Stage of Development and Value 97
7.1.3 Deals by Molecule Type, Molecular Target and Value 98
7.1.4 Table for Licensing Deals Valued Above $100m 100
7.2 Co-development Deals 102
7.2.1 Deals by Region, Year and Value 102
7.2.2 Deals by Stage of Development and Value 103
7.2.3 Deals by Molecule Type, Molecular Target and Value 104
8 Appendix 107
8.1 References 107
8.2 Table of All Clinical Stage Pipeline Products 122
8.3 Abbreviations 139
8.4 Methodology 140
8.4.1 Coverage 140
8.4.2 Secondary Research 140
8.4.3 Market Size and Revenue Forecasts 141
8.4.4 Pipeline Analysis 141
8.4.5 Competitive Landscape 142
8.5 Contact Us 142
8.6 Disclaimer 142

1.1 List of Tables
Table 1: Urologic Oncology, Global, Symptoms of the Most Prevalent Urological Cancers, 2016 10
Table 2: Urologic Oncology, Global, Complications Associated with Bladder, Kidney, Prostate and Testicular Cancers 13
Table 3: Urologic Oncology, Global, Epidemiology of The Most Prevalent Urological Cancers, 2015 14
Table 4: Urologic Oncology, Optimal and Actual Chemotherapy Usage Rates Across All Cancer Stages, 2010 19
Table 5: Urologic Oncology, Global, Reconstructive Surgery following Bladder Cancer Resection, 2016 20
Table 6: Urologic Oncology, Optimal and Actual Radiation Therapy Usage Rates in US, 1995–2000 21
Table 7: Urologic Oncology Therapeutics Market, Global, Approved Indications for Zytiga, 2016 24
Table 8: Urologic Oncology Therapeutics Market, Global, Approved Indications for Xtandi, 2016 25
Table 9: Urologic Oncology Therapeutics Market, Global, Approved Indications for Sutent, 2016 27
Table 10: Urologic Oncology Therapeutics Market, Global, Approved Indications for Votrient, 2016 28
Table 11: Urologic Oncology Therapeutics Market, Global, Approved Indications for Inlyta, 2016 29
Table 12: Urologic Oncology Therapeutics Market, Global, Approved Indications for Jevtana, 2016 30
Table 13: Urologic Oncology Therapeutics Market, Global, Approved Indications for Xofigo, 2016 31
Table 14: Urologic Oncology Therapeutics Market, Global, Approved Indications for Provenge, 2016 32
Table 15: Urologic Oncology Therapeutics Market, Global, Approved Indications for Opdivo, 2016 34
Table 16: Urologic Oncology, Global, Usage of Generics Across Key Indications, 2016 74
Table 17: Urologic Oncology, Global, Licensing Deals Valued Above $100m, 2006–2016 100
Table 18: Urologic Oncology, Global, Co-development Deals Valued Above $100m, 2006–2016 106
Table 19: Oncology, Global, All Clinical Trial Stage Pipeline Products, 2016 122
Table 20: Abbreviations 139

1.2 List of Figures
Figure 1: Urologic Oncology, Major Markets, Treatment Usage Patterns for Bladder Cancer, Patients (’000), 2015-2022 14
Figure 2: Urologic Oncology, Major Markets, Treatment Usage Patterns for Kidney Cancer, Patients (’000), 2015–2022 15
Figure 3: Urologic Oncology, Major Markets, Treatment Usage Patterns for Prostate Cancer, Patients (’000), 2015-2022 16
Figure 4: Urologic Oncology, Major Markets, Treatment Usage Patterns for Testicular Cancer, Patients (’000), 2015–2022 17
Figure 5: Urological Cancer, Global, Key Marketed Products and Approved Indications, 2015 23
Figure 6: Urologic Oncology Therapeutics Market, Global, Annual Revenues for Zytiga ($bn), 2011–2022 25
Figure 7: Urologic Oncology Therapeutics Market, Global, Annual Revenues for Xtandi ($bn), 2012–2022 26
Figure 8: Urologic Oncology Therapeutics Market, Global, Annual Revenues for Sutent ($bn), 2006–2022 27
Figure 9: Urologic Oncology Therapeutics Market, Global, Annual Revenues for Votrient ($bn), 2010–2022 28
Figure 10: Urologic Oncology Therapeutics Market, Global, Annual Revenues for Inlyta ($m), 2012–2022 29
Figure 11: Urologic Oncology Therapeutics Market, Global, Annual Revenues for Jevtana ($m), 2012–2022 31
Figure 12: Urologic Oncology Therapeutics Market, Global, Annual Revenues for Xofigo ($bn), 2013–2022 32
Figure 13: Urologic Oncology Therapeutics Market, Global, Annual Revenues for Provenge ($m), 2010–2022 33
Figure 14: Urologic Oncology Therapeutics Market, Global, Annual Revenues for Opdivo ($bn), 2015–2022 34
Figure 15: Urologic Oncology Therapeutics Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2016 35
Figure 16: Urologic Oncology Therapeutics Market, Global, Pipeline for Oncology by Stage of Development, Molecule Type and Program Type, 2016 37
Figure 17: Urologic Oncology Therapeutics Market, Global, Pipeline for Key Oncology Indications by Stage of Development, 2016 38
Figure 18: Urologic Oncology Therapeutics Market, Global, Pipeline for Key Oncology Indications by Molecule Type, 2016 39
Figure 19: Urologic Oncology Therapeutics Market, Global, Pipeline for Oncology by Molecular Target, 2016 41
Figure 20: Urologic Oncology Therapeutics Market, Global, Pipeline by Molecular Target and Stage of Development, 2016 42
Figure 21: Urologic Oncology Therapeutics Market, Global, Pipeline for Key Oncology Indications by Molecular Target, 2016 43
Figure 22: Urologic Oncology Therapeutics Market, Global, Urologic Clinical Trial by Indication (%), 2006–2016 44
Figure 23: Urologic Oncology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006–2016 45
Figure 24: Urologic Oncology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006–2016 46
Figure 25: Urologic Oncology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006–2016 47
Figure 26: Urologic Oncology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006–2016 48
Figure 27: Urologic Oncology Therapeutics Market, Global, Clinical Trial Size by Stage of Development (months), 2006–2016 49
Figure 28: Urologic Oncology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006–2016 50
Figure 29: Urologic Oncology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006–2016 51
Figure 30: Urologic Oncology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006–2016 52
Figure 31: Urologic Oncology Therapeutics Market, Global, Clinical Trial Size by Stage of Development (participants), 2006–2016 53
Figure 32: Urologic Oncology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006–2016 54
Figure 33: Urologic Oncology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006–2016 55
Figure 34: Urologic Oncology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006–2016 56
Figure 35: Urologic Oncology Therapeutics Market, Global, Clinical Program Size by Stage of Development (months), 2006–2016 57
Figure 36: Urologic Oncology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006–2016 58
Figure 37: Urologic Oncology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006–2016 59
Figure 38: Urologic Oncology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006–2016 60
Figure 39: Urologic Oncology Therapeutics Market, Global, Revenue Forecast for atezolizumab ($bn), 2016–2022 62
Figure 40: Urologic Oncology Therapeutics Market, Global, Revenue Forecast for Durvalumab ($bn), 2017–2022 63
Figure 41: Urologic Oncology Therapeutics Market, Global, Revenue Forecast for Durvalumab + Tremelimumab ($m), 2018–2022 64
Figure 42: Urologic Oncology Therapeutics Market, Global, Revenue Forecast for Apalutamide ($m), 2018–2022 65
Figure 43: Urologic Oncology Therapeutics Market, Global, Revenue Forecast for Avelumab ($m), 2016–2022 66
Figure 44: Urologic Oncology Therapeutics Market, Global, Revenue Forecast for Tivozanib ($m), 2016–2022 67
Figure 45: Urologic Oncology Therapeutics Market, Global, Revenue Forecast for Eoquin ($m), 2017–2022 68
Figure 46: Urologic Oncology Therapeutics Market, Global, Revenue Forecast for Prostvac ($m), 2016–2022 69
Figure 47: Urologic Oncology, Global, Market Size ($bn), 2015–2022 71
Figure 48: Urologic Oncology, Global, Market Size ($bn), 2015–2022 72
Figure 49: Urologic Oncology, Global, Annual Revenue Forecast for Key Products ($bn), 2015–2022 73
Figure 50: Urologic Oncology, Global, Annual Revenue Forecast for Androgen Receptor ($bn), 2015–2022 75
Figure 51: Urologic Oncology, Global, Annual Revenue Forecast for Programmed Cell Death Protein 1 Inhibitor ($bn), 2015–2022 76
Figure 52: Urologic Oncology, Global, Annual Revenue Forecast for VEGF Inhibitors ($bn), 2015–2022 77
Figure 53: Urologic Oncology, Global, Annual Revenue Forecast for GNRH Inhibitors ($m), 2015–2022 78
Figure 54: Urologic Oncology, Global, Annual Revenue Forecast for Tubulin Inhibitors ($m), 2015–2022 79
Figure 55: Urologic Oncology, Global, Annual Revenue Forecast for CTLA-4 ($m), 2017–2022 79
Figure 56: Urologic Oncology, Global, Companies by Type, Cluster by Growth and Market Share, 2015–2022 80
Figure 57: Urologic Oncology Therapeutics Market, Global, Forecast Revenues by Company, 2015–2022 82
Figure 58: Urologic Oncology Therapeutics Market, Global, Forecast Market Share by Company (%), 2015–2022 83
Figure 59: Urologic Oncology, Global, Companies by Compound Annual Growth Rate (%), 2015–2022 84
Figure 60: Urologic Oncology, Global, Revenues by Product Type, 2015–2022 85
Figure 61: Urologic Oncology, Global, Pfizer Urologic Oncology Annual Revenue Forecast ($bn), 2015–2022 86
Figure 62: Urologic Oncology, Global, Novartis AG Annual Revenue Forecast ($bn), 2015–2022 87
Figure 63: Urologic Oncology, Global, Johnson & Johnson Annual Revenue Forecast ($bn), 2015–2022 87
Figure 64: Urologic Oncology, Global, Astellas Pharma Inc. Annual Revenue Forecast ($bn), 2015–2022 88
Figure 65: Urologic Oncology, AstraZeneca Plc. Annual Revenue Forecast ($bn), 2015–2022 89
Figure 66: Urologic Oncology, Bristol-Myers Squibb Annual Revenue Forecast ($bn), 2015–2022 90
Figure 67: Urologic Oncology, Global, Companies by Type, 2015–2022 91
Figure 68: Urologic Oncology, Global, Pipeline, High-Activity and Late-Stage Developers by Level of Urological Cancer Specialization, 2015–2022 92
Figure 69: Urologic Oncology, Global, Proportion of Total Company Revenue Attributed to Urological Cancer, 2015–2022 93
Figure 70: Urologic Oncology, Global, Proportion of Total Company Revenue Attributed to Urological Cancers, Top Six Companies ($bn), 2015–2022 94
Figure 71: Urologic Oncology, Global, Licensing Deals, 2006–2016 96
Figure 72: Urologic Oncology, Global, Licensing Deals by Indication and Value, 2006–2016 97
Figure 73: Urologic Oncology, Global, Licensing Deals, 2006–2016 98
Figure 74: Urologic Oncology, Global, Licensing Deals by Molecule Type and Molecular Target, 2006–2016 99
Figure 75: Urologic Oncology, Global, Co-development Deals, 2006–2016 102
Figure 76: Urologic Oncology, Global, Co-development Deals by Indication and Value, 2006–2016 103
Figure 77: Urologic Oncology, Global, Co-development Deals, 2006–2016 104
Figure 78: Urologic Oncology, Global, Co-development Deals by Molecule Type and Molecular Target, 2006–2016 105

$4,995.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838



Browse All Reports